b'Scientific Session Abstracts SUNDAY APRIL 21, 2024Indication OR (95% CI) P-ValueAsymptomatic 1 (reference) -Claudication 1.02 (0.53-1.97) 0.953Rest Pain 2.44 (1.28-4.66) 0.007Tissue Loss 2.18 (1.16-4.11) 0.016Acute Ischemia 3.39 (1.77-6.49) 0.001Not Treated 2.53 (1.34-4.77) 0.004Per hour procedure time 1.00 (1.00-1.00) 0.001Preoperative P2Y12 Antagonist TherapyNone 1 (reference) -Clopidogrel 0.81 (0.73-0.91) 0.001Prasugrel 1.14 (0.58-2.24) 0.697Ticagrelor 0.93 (0.49-1.75) 0.818Other 0.81 (0.30-2.16) 0.668No, for medical reasons 0.69 (0.50-0.96) 0.027Non-compliant 1.35 (0.75-2.45) 0.314Pre-operative Anticoagulation TherapyNone 1 (reference) -Warfarin 1.38 (1.16-1.65) 0.001Dabigatran 1.06 (0.49-2.31) 0.874Rivaroxaban 1.42 (1.15-1.75) 0.001Other 1.54 (1.29-1.85) 0.001No, for medical reasons 1.14 (0.74-1.74) 0.548Non-compliant 2.35 (1.27-4.35) 0.007* Presented are odds ratios (95% confidence interval) from a multivariable model adjusting for age, sex, race, diabetes, dialysis, CHF, prior CABG, COPD, smoking, use of aspirin, statin, anticoagulation, BMI, urgency, indication and total procedural time.42 NDANNUAL MEETING|APRIL 1921, 2024|OCEANSIDE, CA 81'